Latest Wearables News

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

Nanoveu, via its subsidiary EMASS, has expanded its U.S. sales network with key manufacturer representatives to fast-track adoption of its ECS-DoT ultra-low power Edge AI chip across critical OEM hubs.

dorsaVi Ltd has unveiled Artemis Labs, a new subsidiary focused on developing advanced AI, sensor, and robotics technologies powered by cutting-edge RRAM. This initiative aims to transform human movement data into intelligent robotic and healthcare applications.

dorsaVi Ltd has raised A$5 million through a strategic placement to accelerate development of its next-generation RRAM-enabled sensors and robotics platforms, signaling a bold expansion into edge AI and neuromorphic computing.

AnteoTech has mutually terminated its A$1.4 million Queensland government grant to avoid costly co-investment, opting instead for cheaper third-party testing to advance its Ultranode™ battery technology.

Nanoveu Limited advances its proprietary 16nm ECS-DoT chip fabrication, targeting completion by Q4 2025, supported by a strategic partnership and expanded engineering teams across multiple continents.

dorsaVi Ltd is expanding its RRAM technology evaluation to next-generation robotics, aiming to deliver sub-millisecond reflexes that could revolutionize safety and dexterity in collaborative robots and wearables.

Control Bionics capped a record FY25 with 15% revenue growth, driven by US market gains and expanding NeuroNode and NeuroStrip technologies. The company also achieved a US profitability milestone and is close to finalizing key distribution partnerships.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.

dorsaVi has acquired exclusive global rights to advanced RRAM technology, promising major performance gains in its biomedical sensors, while securing key contracts and raising $2.44 million to fuel US market growth.